Rybelsus vs Ozempic: tablet or pen, doses, cost and switching
The short answer
Rybelsus vs Ozempic compares two semaglutide brands approved for adults with type 2 diabetes. Rybelsus is a once-daily tablet. Ozempic is a once-weekly pen, and there's a daily Ozempic tablet too. The Ozempic pen costs $349 a month self-pay through NovoCare Pharmacy. Rybelsus has a savings offer of as little as $25 with commercial coverage.
Key takeaways
- Both contain semaglutide from Novo Nordisk, and both are for adults with type 2 diabetes.
- Only the Ozempic injection has a kidney use, in adults with type 2 diabetes and chronic kidney disease.
- The label says Rybelsus and Ozempic tablets don't swap milligram for milligram. Rybelsus 7 mg pairs with Ozempic tablets 4 mg.
- Novo Nordisk says Rybelsus is being replaced by the Ozempic pill, and existing Rybelsus savings offers can be used for Ozempic.
- With commercial insurance that covers them, each savings offer goes as low as $25. The Ozempic pen is $349 cash through NovoCare.
Ozempic vs Rybelsus, side by side
| Ozempic | Rybelsus | |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| Maker | Novo Nordisk | Novo Nordisk |
| FDA-approved uses |
|
|
| How it is taken | weekly (multi-dose pen); daily (tablet) | daily (tablet) |
| Strengths | 0.25 to 9 mg | 3 to 14 mg |
| Label starting dose |
|
|
| Cheapest verified self-pay | No self-pay price listed | No self-pay price listed |
| With covering commercial insurance | No savings-card price listed | $25 with the manufacturer card |
| Medicare GLP-1 Bridge | No | No |
| Label | Revised: 5/2026 (DailyMed version 20) | Revised: 1/2026 (DailyMed version 14) |
| Reaction | Ozempic 1 mg | Placebo |
|---|---|---|
| Nausea | 20.3% | 6.1% |
| Vomiting | 9.2% | 2.3% |
| Diarrhea | 8.8% | 1.9% |
| Abdominal pain | 5.7% | 4.6% |
| Constipation | 3.1% | 1.5% |
| Reaction | Semaglutide tablets 14 mg | Placebo |
|---|---|---|
| Nausea | 20% | 6% |
| Abdominal Pain | 11% | 4% |
| Diarrhea | 10% | 4% |
| Decreased appetite | 9% | 1% |
| Vomiting | 8% | 3% |
| Constipation | 5% | 2% |
Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.
Rybelsus and Ozempic are the two Novo Nordisk semaglutide brands for adults with type 2 diabetes. The choice looks simple: a pill every morning or a pen once a week. It’s less simple than that, because Ozempic also comes as a tablet, and that tablet shares one FDA label with Rybelsus. This comparison follows the FDA labels (Revised: 5/2026 (DailyMed version 20) for the Ozempic pen, Revised: 1/2026 (DailyMed version 14) for Rybelsus and Ozempic tablets) and our price records.
Rybelsus or Ozempic: which suits whom?
- You’re comfortable with one injection a week. The Ozempic pen spares you a daily routine built around an empty stomach. It’s also the only one of the three products approved for kidney risk reduction in type 2 diabetes with chronic kidney disease, and it has a self-pay price.
- You want to avoid needles and can keep to the label’s morning rules every day. Rybelsus fits that. It has no kidney use, and Novo Nordisk states it’s being replaced by the Ozempic pill.
- You’re thinking about tablets for the longer term. Ozempic tablets have their own strengths, and they’re the tablet the maker is moving toward.
- You’re comparing cost. If you’re commercially insured with coverage, you can get either brand for as little as $25 with a savings offer. If you’re paying cash, the Ozempic pen has a self-pay price.
- You’re on Medicare. All of them are type 2 diabetes medicines that Part D can cover, and none is part of the Medicare GLP-1 Bridge.
Both brands contain semaglutide, but each product has its own label section, approved uses and dose numbers. If you take Rybelsus now, ask your prescriber two things: when you might be moved to the Ozempic pill, and whether a weekly pen would suit you better than a daily tablet.
What is each approved for?
Every use is in adults with type 2 diabetes.
| Blood sugar control | Cardiovascular risk | Kidney disease | |
|---|---|---|---|
| Ozempic injection | Yes | Adults with established cardiovascular disease | Adults with chronic kidney disease |
| Ozempic tablets | Yes | Adults at high risk for these events | Not listed |
| Rybelsus | Yes | Adults at high risk for these events | Not listed |
So the injection and the tablets differ on two points: the wording of the cardiovascular use, and the kidney use, which belongs to the injection alone. Neither brand has a weight-loss use. The semaglutide brand approved for that is Wegovy, compared with Rybelsus here.
The label also says the effectiveness of Ozempic tablets rests on the clinical studies of Rybelsus.
How are they taken?
Ozempic pen. One injection a week, on the same day each week, at any time of day, with or without meals. The pen is multi-dose: at a steady dose, one pen holds four weekly injections. Once in use, it can be kept for 56 days at room temperature or in a refrigerator.
Rybelsus (and Ozempic tablets). One tablet a day, and the routine is strict:
- in the morning, on an empty stomach;
- with up to 4 ounces of plain water and no other liquid;
- then at least 30 minutes before food, other drinks or other oral medicines;
- never more than one tablet a day.
The tablets are stored at room temperature in the original bottle, which protects them from moisture. You don’t need a refrigerator, which helps when you travel. The trade-off is a daily habit you have to do the same way every morning.
How do the doses compare?
Ozempic pen: 0.25 mg, 0.5 mg, 1 mg, 2 mg, once weekly. The label starts at 0.25 mg for 4 weeks, moves to 0.5 mg, and allows 1 mg and then 2 mg if more blood sugar control is needed, each after at least 4 weeks. The maximum is 2 mg.
Rybelsus: 3 mg, 7 mg, 14 mg, once daily. Days 1 to 30 are at 3 mg, a dose the label says is not effective for blood sugar control. Days 31 to 60 are at 7 mg. From day 61 the dose may rise to 14 mg if more control is needed.
Ozempic tablets: 1.5 mg, 4 mg, 9 mg, once daily, on the same 30-day pattern.
The milligram numbers can’t be compared across these three. A weekly injected dose and a daily swallowed dose are measured on different scales, and even the two tablets don’t line up: the label says Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis. The titration schedule tool shows each path by date.
What does each cost?
Ozempic pen:
- Self-pay through NovoCare Pharmacy: $349 a month for 0.25 mg, 0.5 mg or 1 mg, and $499 a month for 2 mg.
- New self-pay patients: $199 for each of the first two monthly fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349.
- Savings offer, with commercial insurance that covers Ozempic: as little as $25.
- List price (the full price before any discount): $1,027.51 per pen.
Rybelsus: one price, the savings offer. With commercial insurance that covers Rybelsus, eligible patients pay as little as $25.
In plain terms, if your commercial plan covers both, the savings offers put them at the same floor. If you pay cash, ask your pharmacy for its cash price for the tablets and set it against the pen’s price. The Ozempic cost page, the Rybelsus cost page and the cost calculator go further, and our savings card guide explains the offers.
Does insurance or Medicare cover them?
Commercial plans commonly cover semaglutide for type 2 diabetes, often with prior authorization (the plan’s approval before it pays) or a requirement to try another medicine first. A plan may prefer one form over another, so ask about the pen and the tablets separately. Both savings offers exclude people on Medicare, Medicaid and other government programs.
For Medicare, CMS lists type 2 diabetes as an indication eligible for Part D coverage, so either brand runs through your Part D plan. One change applies to both. Under the Medicare Drug Price Negotiation Program, the negotiated price for a 30-day supply of semaglutide (Ozempic, Rybelsus, Wegovy) is $274 from January 1, 2027. What you pay will still depend on your plan’s cost sharing. The Medicare guide has the wider rules.
How do the side effects compare?
The same molecule is behind both, and both labels put gastrointestinal (stomach and bowel) reactions first. The figures below come from each product’s own trials and aren’t a ranking of pen against tablet.
Ozempic injection. In its placebo-controlled trials, nausea was reported by 15.8 percent of patients on 0.5 mg and 20.3 percent on 1 mg, against 6.1 percent on placebo. Gastrointestinal reactions overall occurred in 32.7% on 0.5 mg and 36.4% on 1 mg, compared with 15.3% on placebo. Injection site reactions were reported in 0.2% of patients on Ozempic.
Rybelsus. In its placebo-controlled trials, nausea was reported by 11 percent of patients on 7 mg and 20 percent on 14 mg, against 6 percent on placebo. Gastrointestinal reactions overall occurred in 32% on 7 mg and 41% on 14 mg, compared with 21% on placebo.
Both labels say most reports of nausea, vomiting or diarrhea came during dose escalation, while the dose was going up. Both carry the boxed warning about thyroid C-cell tumors and the same rule against use by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it). Both warn about low blood sugar when used with insulin or a sulfonylurea (a type of diabetes medicine).
Can you switch between Rybelsus and Ozempic?
Here the label is unusually specific, and it covers three moves.
- Rybelsus to Ozempic tablets, or back. Not during the first 30 days. After that, Rybelsus 7 mg corresponds to Ozempic tablets 4 mg, and Rybelsus 14 mg to Ozempic tablets 9 mg. The new tablet is started the day after the old one is stopped.
- Ozempic pen to Rybelsus. Patients on the 0.5 mg injection may switch to Rybelsus 7 mg or 14 mg, starting one week after the last injection.
- Ozempic pen to Ozempic tablets. Patients on the 0.5 mg injection may switch to Ozempic tablets 4 mg or 9 mg, starting one week after the last injection.
The label gives no instruction for other injection doses, and the Ozempic injection label gives no instructions for switching to the pen from another medicine. Those gaps are for your prescriber to fill. The pairings above are the label’s own. They aren’t a formula to apply yourself.
Our guide to moving from Rybelsus to the Ozempic pill covers the first move in detail, and the switching planner shows the label text for any pair. For other medicines in this class, see the comparison hub or Ozempic vs Trulicity.
Frequently asked questions
Is Rybelsus the pill form of Ozempic?
Rybelsus and Ozempic both contain semaglutide and both come from Novo Nordisk, but they're separate products. Rybelsus is a tablet in 3 mg, 7 mg and 14 mg. Ozempic is a weekly pen, and there are also Ozempic tablets in 1.5 mg, 4 mg and 9 mg. The label says Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis.
Can I switch from the Ozempic pen to Rybelsus?
The label covers one case. Patients taking the 0.5 mg dose of Ozempic injection may switch to Rybelsus, starting 7 mg or 14 mg once daily one week after the last injection. It gives no instruction for other injection doses. Your prescriber decides whether and how to make the change, and it needs a new prescription.
Which costs less, Rybelsus or Ozempic?
With commercial insurance that covers them, both savings offers bring the cost to as little as $25. If you're paying cash, the Ozempic pen costs $349 a month for 0.25 mg, 0.5 mg or 1 mg and $499 for 2 mg through NovoCare Pharmacy.
Is Rybelsus being replaced by the Ozempic pill?
Novo Nordisk states that Rybelsus is being replaced by the Ozempic pill and that existing Rybelsus savings offers can be used for Ozempic. The shared label pairs Rybelsus 7 mg with Ozempic tablets 4 mg and Rybelsus 14 mg with Ozempic tablets 9 mg.
Do Rybelsus and Ozempic have the same side effects?
Both labels list gastrointestinal reactions as the most common, and both carry the boxed warning about thyroid C-cell tumors. The rates come from separate trials. In Ozempic's placebo-controlled trials, nausea was reported by 15.8 percent on 0.5 mg and 20.3 percent on 1 mg. In the Rybelsus trials, it was 11 percent on 7 mg and 20 percent on 14 mg.
Sources (23)
- 1.FDA label (DailyMed): Ozempic prescribing information, section 2.1
“Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.”
- 2.FDA label (DailyMed): Ozempic prescribing information, section 3
“Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens”
- 3.FDA label (DailyMed): Ozempic prescribing information, section 16
“After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the pen cap on when not in use. OZEMPIC should be protected from excessive heat and sunlight.”
- 4.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 14.1
“has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus”
- 5.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
- 6.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.3
“When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.”
- 7.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
“One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.”
- 8.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water”
- 9.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 10.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 11.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.2
“Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).”
- 12.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
“One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily.”
- 13.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 16
“Store RYBELSUS and OZEMPIC tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store and dispense in the original bottle.”
- 14.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 16
“Store tablets in the original bottle until use to protect tablets from moisture. Store product in a dry place away from moisture.”
- 15.FDA label (DailyMed): Ozempic prescribing information, section 4
“A personal or family history of MTC or in patients with MEN 2”
- 16.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
“A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
- 17.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 18.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
- 19.
- 20.
- 21.
- 22.
- 23.
